Liraglutide: difference between revisions
Diff·revision 21 → 22·18:12, 4 Jul 2025
Difference between revision 21 and revision 22 of Liraglutide. 3 lines changed; the page grew by 547 bytes.
| Revision 21 — 05:54, 12 Jun 2025 DrTitration (talk) expand §Practical differences from weekly agents 5,268 bytes ±0 | Revision 22 — 18:12, 4 Jul 2025 SemaglutideSasha (talk) split §Pharmacology into receptor binding and downstream signalling 5,815 bytes +547 | ||
|---|---|---|---|
| 42 | Conversely, the peak-to-trough ratio within a dosing interval is higher than for a weekly agent, and daily injection is a larger practical burden. Discontinuation rates in head-to-head comparisons have favoured weekly agents.{{r|knudsen2019}} | 42 | Conversely, the peak-to-trough ratio within a dosing interval is higher than for a weekly agent, and daily injection is a larger practical burden. Discontinuation rates in head-to-head comparisons have favoured weekly agents.{{r|knudsen2019}} |
| 43 | 43 | ||
| + | 44 | For anyone examining a [[Certificate of analysis|certificate]] on liraglutide, the analytical caution is the same as for other acylated peptides: hydrophobicity requires a strong organic gradient, and the self-associated forms mean that size-based methods can report an apparent high-molecular-weight species that is a reversible oligomer rather than an aggregate. See [[Peptide aggregation]].{{r|usp1503}} | |
| + | 45 | ||
| 44 | == References == | 46 | == References == |
| 45 | {{reflist}} | 47 | {{reflist}} |
| ⋮ | ⋮ | ||
| 47 | <ref name="lau2015">Lau J, Bloch P, Schäffer L, et al. "Discovery of the once-weekly glucagon-like peptide-1 analog semaglutide." ''Journal of Medicinal Chemistry'' 58(18):7370–7380 (2015). PMID 26308095.</ref> | 49 | <ref name="lau2015">Lau J, Bloch P, Schäffer L, et al. "Discovery of the once-weekly glucagon-like peptide-1 analog semaglutide." ''Journal of Medicinal Chemistry'' 58(18):7370–7380 (2015). PMID 26308095.</ref> |
| 48 | <ref name="marso2016">Marso SP, Daniels GH, Brown-Frandsen K, et al. "Liraglutide and cardiovascular outcomes in type 2 diabetes." ''New England Journal of Medicine'' 375(4):311–322 (2016). DOI:10.1056/NEJMoa1603827. PMID 27295427.</ref> | 50 | <ref name="marso2016">Marso SP, Daniels GH, Brown-Frandsen K, et al. "Liraglutide and cardiovascular outcomes in type 2 diabetes." ''New England Journal of Medicine'' 375(4):311–322 (2016). DOI:10.1056/NEJMoa1603827. PMID 27295427.</ref> |
| + | 51 | <ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, ''Quality Attributes of Synthetic Peptide Drug Substances''.</ref> | |
| 49 | 52 | ||
| 50 | == See also == | 53 | == See also == |